×

Methods and products for transfecting cells

  • US 9,605,278 B2
  • Filed: 07/28/2016
  • Issued: 03/28/2017
  • Est. Priority Date: 12/05/2011
  • Status: Active Grant
First Claim
Patent Images

1. A therapeutic composition, comprising a gene-edited hematopoietic cell, wherein:

  • the gene-edited hematopoietic cell comprises;

    an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, the gene-editing protein comprising a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell; and

    a double-strand break in its DNA, the double-strand break being caused by the gene-editing protein and reducing the function of one or more of CCR5 and CXCR4.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×